This study is looking at the safety and potential side effects of an imaging agent called 4-\[18F\]Fluoro-1-Naphthol (or \[18F\]4FN) when used with PET/CT scans. This is for people who have chronic graft versus host disease (GVHD), a condition where donated cells attack the patient's body. Researchers want to see if the images from \[18F\]4FN PET/CT can show where and how severe your chronic GVHD is, especially in your joints. They also want to see if these images can predict GVHD before symptoms appear. You can join if you are 18 or older, have chronic GVHD affecting your joints, and meet other health requirements. The study aims to see if this imaging method works as expected. The current recruitment status is unclear.

Study design

This is an interventional pilot study with a planned enrollment of 16 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will receive \[18F\]4FN by IV and undergo PET-CT imaging. The primary endpoint for safety will be measured through study completion, an average of 1 year.

Compensation

Not stated in the trial record.

Follow-up

Safety and adverse events will be monitored through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.